Do you have questions?
We have answers.
CDMO
At LTS, we have a somewhat unique model where we support partners who are adopting an LTS platform as well as those who have developed their own technology and need a high-quality manufacturing partner that can deliver global volumes.
Supporting innovation from concept to market
Bringing a pharmaceutical product to market requires far more than a promising molecule. It demands careful development, robust process design and a manufacturing strategy that can support the entire development process from feasibility, first prototypes, clinical trials through to commercial launch and lifecycle management. A CDMO provides the capabilities needed to move efficiently through these stages while helping partners maintain focus on their core scientific objectives.
A CDMO typically offers integrated services across the full product lifecycle. These may include formulation development, analytical testing, process optimisation, scale-up, clinical manufacturing, validation, and commercial production.
By bringing these functions together within one consistent and valued partnership, pharma companies create a more seamless path from early development to market supply. This integrated approach can help reduce complexity, improve coordination, and support greater continuity across each phase of development.
Working with a CDMO offers important strategic advantages. It reduces the need for major investment in facilities, equipment, and specialised skils, while providing access to proven technical knowledge and manufacturing experience. In the case of LTS, this expertise and know how extends across a wide range of delivery technologies including Transdermal Therapeutic Systems, Oral Thin Films, Microneedle Array Patches, Topical Patch Systems, On Body Delivery Systems and Nasal Drug Delivery. To find out more about our technology platforms click here.
For our partners, this model offers flexibility and speed, allowing its teams to adapt to changing development needs, respond to regulatory expectations and scale production with confidence.
Expertise matters
In pharmaceutical development, expertise is essential. Each product presents unique scientific, technical, and regulatory challenges, and success depends on the ability to manage them with precision. A strong CDMO partner does more than provide capacity. It contributes insight, continuity and execution across the entire journey, helping ensure that development and manufacturing are aligned with long-term product goals.
A partner for progress
As the pharmaceutical industry continues to evolve, the role of the CDMO becomes increasingly important. Pharma companies are seeking trusted partners who can combine innovation with operational excellence and support the delivery of high-quality products to patients around the world.
For more information on our CDMO capabilities click here
Pharmaceutical development, from first principles, feasibility, prototyping and clinical trials through to manufacturing of high volumes is defined by complexity, precision and high standards. As programmes move from concept to commercialisation, many companies choose to partner with a contract manufacturer that is equipped with specialised expertise, dedicated infrastructure and reliability through experience.
Necessarily contract manufacturing in pharma is more than an outsourcing arrangement. It is a strategic collaboration that helps bring products to market efficiently, consistently and in compliance with ever evolving, ever increasingly demanding regulatory expectations. For organisations seeking to scale with confidence, the right partner can make a seismic impact at every stage of the journey.
At its best, contract manufacturing represents a seamless extension of your own organisation. It allows pharmaceutical companies to focus on innovation, development and market strategy while relying on an experienced partner to manage your manufacturing requirements.
This model is particularly valuable in an industry where quality and continuity of supply are essential to ensure patients continue to benefit from often lifesaving or life enhancing therapies. Only by working with a trusted manufacturing partner, can companies reduce the burden of capital investment while responding with agility to shifting market needs.
The pharmaceutical sector operates under strict regulatory scrutiny and exceptionally low tolerance for error. Every process must be built to protect product quality, ensure traceability, and support the highest levels of patient safety.
Contract manufacturing helps companies meet these demands while maintaining operational agility. It can shorten time to market, improve production efficiency, and provide access to specialised equipment or expertise that may not be available internally. For many organisations, it also offers a more flexible path to growth without compromising standards.
The value of contract manufacturing extends well beyond production itself. A strong partner contributes insight during planning, alignment during development and consistency during scale-up and supply.
That value can only be created through early collaboration. When manufacturing considerations are addressed from the outset, it becomes easier to manage specifications, reduce risk and establish a more reliable path forward. Clear communication around timelines, sourcing, and quality expectations also helps prevent delays and supports long-term operational stability.
Not all manufacturing partnerships are created equal. In pharma, the best outcomes depend on technical capability, regulatory discipline and a shared commitment to quality.
A strong contract manufacturing partner should offer more than capacity. It should bring proven experience, robust systems and the ability to work as an extension of your team. Just as importantly, it should support transparent planning and responsive execution, ensuring that every step is aligned with your programme goals.
When managed with the right partner, it becomes a foundation for sustainable growth. The result is not simply outsourced production, but a relationship built to support quality, continuity and long-term success.
TTS
Most modern patches consist of (at least) three essential layers:
- Backing Layer: The outermost waterproof film that protects the medication from environmental factors like water or friction.
- Drug Containing, adhesive layer: The core where the medication is stored, dissolved or dispersed within a solid polymer adhesive layer.
- Release Liner: A protective film that is peeled off just before applying the patch to expose the adhesive.
Most modern patches consist of (at least) three essential layers:
- • Backing Layer: The outermost waterproof film that protects the medication from environmental factors like water or friction.
- • Drug Containing, adhesive layer: The core where the medication is stored, dissolved or dispersed within a solid polymer adhesive layer
- • Release Liner: A protective film that is peeled off just before applying the patch to expose the adhesive.
Once applied, the drug moves from the patch into the stratum corneum (the skin’s outermost barrier layer). It then diffuses through the deeper epidermis and dermis until it reaches capillaries, which absorb the drug into the general circulation.
- Avoids ‘First-Pass’ Metabolism: By bypassing the digestive system and therefore the initial metabolization by the liver, the drug remains more potent and causes fewer gastrointestinal side effects.
- Consistent Blood Levels: TTS provides a steady, controlled release, preventing the sudden peaks and troughs in medication levels often seen with tablets.
- Improved Compliance: Patches are non-invasive, easy to apply, and can last from several hours to 7 days, making them ideal for patients who forget daily pills or have difficulty swallowing.
- Instant Termination: If an adverse reaction is experienced, the drug delivery can be stopped simply by removing the patch.
Patches are widely used for various conditions, such as Smoking Cessation, Pain Management, Hormone Therapy and Chronic Conditions such as Alzheimer’s or Parkinson’s disease, angina pectoris and hypertension.
To find out more about our technology click here